Zenas BioPharma (NASDAQ:ZBIO) Director Hongbo Lu Purchases 3,768 Shares

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Hongbo Lu bought 3,768 shares of Zenas BioPharma stock in a transaction dated Tuesday, March 31st. The stock was purchased at an average cost of $18.63 per share, with a total value of $70,197.84. Following the completion of the acquisition, the director directly owned 426,736 shares in the company, valued at approximately $7,950,091.68. The trade was a 0.89% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Hongbo Lu also recently made the following trade(s):

• On Wednesday, February 11th, Hongbo Lu bought 25,985 shares of Zenas BioPharma stock. The stock was purchased at an average cost of $22.50 per share, with a total value of $584,662.50.

Zenas BioPharma Trading Up 5.4%

NASDAQ:ZBIO opened at $21.46 on Friday. The company has a market capitalization of $1.23 billion, a PE ratio of -2.75 and a beta of -0.54. Zenas BioPharma, Inc. has a 52-week low of $6.11 and a 52-week high of $44.60. The stock’s 50 day moving average price is $23.15 and its 200 day moving average price is $27.22. The company has a quick ratio of 5.61, a current ratio of 5.61 and a debt-to-equity ratio of 0.32.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings data on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ZBIO shares. Citigroup decreased their price target on shares of Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Morgan Stanley lifted their price objective on shares of Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 17th. Wall Street Zen cut shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Saturday, March 21st. HC Wainwright reiterated a “buy” rating and set a $44.00 target price on shares of Zenas BioPharma in a research note on Tuesday, March 17th. Finally, Wedbush reissued an “outperform” rating and set a $45.00 price target on shares of Zenas BioPharma in a report on Monday, December 22nd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $44.14.

Hedge Funds Weigh In On Zenas BioPharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Federated Hermes Inc. raised its position in Zenas BioPharma by 60.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after buying an additional 703,838 shares during the last quarter. Intech Investment Management LLC boosted its holdings in shares of Zenas BioPharma by 13.9% in the second quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock valued at $128,000 after acquiring an additional 1,607 shares in the last quarter. Creative Planning purchased a new stake in shares of Zenas BioPharma in the third quarter valued at about $264,000. Virtus Investment Advisers LLC acquired a new position in shares of Zenas BioPharma during the fourth quarter worth about $238,000. Finally, Bank of America Corp DE increased its stake in shares of Zenas BioPharma by 32.3% during the second quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock worth $136,000 after acquiring an additional 3,412 shares during the period.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.